Salipro Biotech and Boehringer Ingelheim have entered into a research collaboration to develop drug targets for membrane proteins involved in mental health and cardio-renal-metabolic disease pathology.
Together, the companies aim to advance the discovery and development of novel therapies targeting integral membrane proteins such as ion channels and transporters, as well as G protein-coupled receptors (GPCRs).
Under the terms of the partnership, Boehringer Ingelheim will utilise the Salipro platform technology to stabilse membrane proteins in their native forms — facilitating their use in drug discovery programmes.
This will allow the company to conduct biophysical and structural studies, which will be instrumental in identifying potential therapeutic candidates for clinical development.
Boehringer Ingelheim will pay Salipro research and option payments through the deal, and thecompany is also eligible for downstream milestone payments based on developmental results.
“We are excited to collaborate with the innovative teams at Boehringer Ingelheim,” said Jens Frauenfeld, CEO of Salipro Biotech.
“By combining our Salipro platform technology with Boehringer Ingelheim’s expertise in biophysical and structural studies, we enable new possibilities in drug discovery and development.”